• Embed Doc
  • Readcast
  • Collections
  • CommentGo Back
Download
 
Page 1
NNEEWWSS
 
Brussels October 2005
L
ANCET LASHES OUT AT HOMEOPATHY
 
On 27
th
August the Lancetpublished the study “Arethe clinical effects of ho-meopathy placebo effects?Comparative study of pla-cebo-controlled trials of homeopathy and allopathy”by Ajing Shang. An editorialpredicted “The end of homeopathy”. Editor McCarthy wrote about the bias in the leakedpreliminary report on the science base of home-opathy by the WHO, admitting, however, that“homeopathy is extremely popular and its use is onthe upswing worldwide”.Following this issue, there have been strong reac-tions from all over the academic world demon-strating areas where the article does not meet theminimum conventional criteria for publication inbiomedicine.A letter to the editor and Echamp’s position canbe found on the websitewww.echamp.org. Moreopinions from the scientific world can be found onwww.homeopathycourses.com/lancet.html Hopefully the result of the present polemic will bethat new ways and funds will be found to researchcomplementary medicine and homeotherapy inparticular. It cannot be true that the millions of satisfied users over 200 years are wrong. Nor can itbe right that politically the prerogative of health-care is given to allopathy only.
A
CADEMIC WORLD RESPONDS TO LANCETPUBLICATION
 
Dr. P Fisher, Clinical Director of the Royal Lon-don Homoeopathic Hospital
:
“There is a strongsuspicion that the results are being spun.” Theconclusion that “the clinical effects of homeopa-thy are placebo effects” is based on only 8 un-referenced clinical trials – and no further informa-tion given. Requests to Prof. Egger, who wrote thefirst draft of the study, to disclose the titles of thestudies used, hit a wall of silence.Fisher underlines that all threecurrent meta-analyses on home-opathy (including the one thatwas left out by Shang) show posi-tive results for homeopathy. Heconcludes that the paper is nottransparent and fails to meet thenorms of a good scientific report:“a reader should be able to reproduce it on thebasis of the report”.Others are concerned about the literature reviewin which apparently eligible high quality studieswere left out and others inappropriately included.
Dr. Robert Mathie (website of Faculty of Homeopathy, UK)
: Lancet article is fundamentallyflawed, the paper has not demonstrated thehomeopathy’s lack of benefit. Regrettably, in pub-lishing and commenting on this paper, the journalhas displayed some of these unwelcome attributesof selective analysis and biased reporting. An in-vestment in clinical research in homeopathy needsto be enhanced, not withheld.
European Health Forum Gastein 5-8 October 2005
 
ECHAMP Workshop - 5 October (18h30-20h00)
 
Complementary medicine – an efficient and safe contributionto patient satisfaction?
 
http://www.ehfg.org/en/congress/W4.php 
 
ECHAMP News October 2005Page 2
George Lewith (University of Southampton, UK)
:
 The six studies of conventional interventions arehighly selected. The substances have gone throughfour clinical pharmacological stages of drug test-ing. The vast majority of newly developed do notmake it to that last stage of Phase IV trials. There-fore the trials chosen by Shang had already beenproven to be efficacious. Homeopathic trials startfrom a far less systematic and rigorous evidencebase. There have, after all, been very few RCT’s inhomeopathy which is why there is an absence of evidence.
We are only just beginning to under-stand how to research homeopathy and CAM in general. This seems to be an argument for moreresearch investment, not less.
 
Prof. Iris Bell (University of Arizona, USA)
:
Thepolitics of the homeopathy debate right now are soblatant, as the position against homeopathyignores the observational data and the animal dataand the preclinical data in the literature asthought they did not exist, let alone that theyshow significant effects and unique properties of remedies.
Sally Penrose (Chief Executive of the Faculty of Homeopathy, UK)
: “Patient outcomes studiesat the NHS homeopathic hospitals show that onaverage 70% of patients report positive healthchanges after homeopathic treatments – thesepatients who have usually exhausted all theconventional options first and are coping withintolerable suffering.”
 Mikel Aickin (Biostatistician University Arizona,USA)
: After distinguishing five areas in which theLancet does not meet the minimum conventionalcriteria for publication in medicine, he observes “acontinued degradation of methods in biomedicalresearch, supported by “leading” journals” andponders that it might be time to think about the“End of Biomedical Journals” as we know them.The duty of publishing all funded research andmuch of the unfunded research could be laid inhands of a body like the National Institutesof Health (NIH), through the National Library of Medicine. That would safeguard an operationunder rational regulations.(FB)
S
WISS STUDY DEMONSTRATES THE EFFECT OFHOMEOPATHY IN HYPERACTIVE CHILDREN
 
(FB) A study performed by KIKOM (KollegialenInstanz für Komplementärmedizin der UniversitätBern) and the “Medizinischen UnivertitätsklinikBern” has demonstrated the efficacy of homeo-pathic medicinal products in children with anAttention Deficit Syndrome (ADS). The study waspublished in the “European Journal of Paediat-rics”. The findings are in opposition of the recentlypublished meta-analysis by the “Institut für Sozial-und Präventivmedizin” of the Bern University la-belling homeopathy to be just a placebo effect.An interdisciplinary research team of that Univer-sity directed by Dr. med Heiner Frei came to theconclusion that ADS symptoms like hyper activity,shyness or anxiety decreased by 37 till 63 percent.The learning behaviour improved and the durationof the positive effect was for a longer period of time.From 2001 to 2005 theresearchers followed theeffects of homeopathictreatment in childrenwith ADS. After a neuro-psychological and neuro-logical check the chil-dren were individuallytreated by a homeo-pathic physician. Thedata were collected according to the double blindcross over method. Neither the patient nor thedoctor knew who received the placebo or the realmedicine. During the treatment the children wereregularly examined by a neuro-psychologist.This positive result puts the homeopathictreatment for ADS patients on an equal level withregular medicine, the latter treating the childrenwith medicinal substances which had effects onthe psyche, often with side effects. According toDr. Frei the homeopathic treatment has a favour-able cost effect.
(Source: Deutscher Zentralverein homoepathischer )
I
N MEMORIAM
D
.
 
M
ARIANNE
H
EGER 
 
(FB) For many of us the death of Dr. MarianneHeger came unexpected. Those with whom sheused to work with suspected an illness, however,no clear signals were received about the severity.That made the shock created by her decease evengreater.ECHAMP will rememberMarianne as one of the fewof the first moment whosaw the need for a Euro-pean coalition of manufac-turers of homeopathic me-dicinal products. She de-voted a part of her abun-dant energy in the conver-sion of EACH into ECHAMP.With her vision she had a roadmap clear in hermind and sometimes wondered why others couldnot follow her quick pace.
 
ECHAMP News October 2005Page 3
After becoming a Doctor of medicine in 1986 shefollowed a postgraduate education in naturopathy,homeopathy and acupuncture. She gained practicalexperience in internal medicine and had a privatepractice until 1992. She took positions as a MedicalAdvisor at Bristol-Meyers Squibb and in interna-tional marketing at Knoll AG before becoming Di-rector of Science and Research at the DHU inKarlsruhe.Marianne Heger was the driving force behind manyresearch projects and a great propagator of out-comes and observational studies. That resulted inIIPCOS-1 an international prospective outcomestudy executed in six study centers in Germany,Austria, Switzerland and the USA. Being a memberof among others, the German Association of Ho-meopathic Doctors, the Association of Naturo-pathic Doctors, the American Institute of Health(AIH), the International Homoeopathic MedicalLeague (LMHI), the Homeopathic PharmacopoeiaConvention of the United States (HPCUS), shecould count on a vast network of prominent ho-meopaths and innovative researchers. Her name isconnected with an impressive list of publicationsand projects.Her creative powers, sense of responsibility andextraordinary expertise made her a special person.The overall objective was always to support andexpand the science base of homeopathy – an aimshe pursued with an incredible engagement.Marianne Heger was an ECHAMP Board Memberfrom the founding of the organization in 1999 until2003 during which she was vice-president, theworking group Public Relations and of course theworking group Research. She was 49 years old. Thehomeopathic community will miss her.
ECHAMP Agenda
SEP 29 SG CTD ColgneOCT 5 EHFG ECHAMP Workshop Gastein (Austria)OCT 5-8 European Health Forum Gastein (Austria)OCT 12 WP CEEC KarlsruheOCT 31 SG Nosodes Baden-BadenNOV 24-25 Board Meeting ECHAMP Brussels
N
EW LICENSING FOR HOMEOPATHIC MEDICINES INTHE
UK  
(KC) After long anticipa-tion, the MHRA has startedpublic consultation on newproposals for the licensingof homeopathic medicines.Article 16.2 of the European Medicines Directive(2001/83/EC) allows the UK to introduce ‘NationalRules’ for the licensing of homeopathics in accor-dance with the principles and characteristics of homeopathy as it is practised in the UK.The proposals under Article 16.2 allow for theinclusion of therapeutic indications on the packag-ing of many homeopathic medicines. This is abreakthrough for the homeopathic medicines in-dustry. The fact that therapeutic indications maynow be included on the packaging of licensed ho-meopathic medicines will not only open the prac-tice of homeopathy up to new users but also give itadded credibility as a safe and natural comple-ment to orthodox medicine.It will also allow a broader range of products in-cluding lower potency (less dilute) homeopathicmedicines.Under current licensing arrangements homeopathicproducts either have Product Licences of Right(PLRs) or have been granted homeopathic registra-tions (HRs) under the Simplified Scheme. PLRswere issued in 1971 to all homeopathic productson the market at the time of the Medicines Act1968. Homeopathic products covered by PLRs mayhave indications on pack.The Simplified Scheme wasintroduced in 1992 by Directive92/73/EEC; it does not allowindications. There is norequirement for data todemonstrate efficacy.Present legislation means that, due to the exclu-sion of therapeutic indications on any newlylicensed homeopathic products, consumers can beconfused by both the range of homeopathic prod-ucts available and their purpose. The new legisla-tion will correct an anomalous situation, wherebytwo products can sit side by side, one with indica-tions and the other without, depending when theywere licensed.Under the proposals, OTC type indications will beallowed for specified ailments, based on relevantbibliographic sources (materia medica and other)and practitioner experience. The range of indications will be limited to minor, self-limitingconditions such as travel sickness and nausea,minor skin conditions, hay fever, and muscularpain and stiffness. It will exclude serious diseasessuch as cancer, diabetes, cardiovascular diseases,chronic insomnia or psychiatric conditions.Packaging, point of sale materials and merchan-disers will all be able to contain more information,with a focus on ailments, making it much easierfor individuals to self-select OTC homeopathicremedies and for pharmacists with limited experi-ence of homeopathy to recommend OTC homeo-pathic medicines for acute or first aid conditions.
of 00

Leave a Comment

You must be to leave a comment.
Submit
Characters: ...
You must be to leave a comment.
Submit
Characters: ...